AVDL Key Statistics, Chart & Performance
The current stock price of AVDL is 21.59 USD. In the past month the price increased by 0.89%. In the past year, price increased by 104.94%.
AVDL Latest News, Press Relases and Analysis
AVDL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About AVDL
Company Profile
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Company Info
AVADEL PHARMACEUTICALS
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
DUBLIN DUBLIN D02 IE
CEO: Gregory J. Divis
Employees: 188
Phone: 35319015201
AVADEL PHARMACEUTICALS / AVDL FAQ
Can you describe the business of AVADEL PHARMACEUTICALS?
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Can you provide the latest stock price for AVADEL PHARMACEUTICALS?
The current stock price of AVDL is 21.59 USD. The price increased by 0.05% in the last trading session.
Does AVADEL PHARMACEUTICALS pay dividends?
AVDL does not pay a dividend.
What is the ChartMill technical and fundamental rating of AVDL stock?
AVDL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does AVADEL PHARMACEUTICALS belong to?
AVADEL PHARMACEUTICALS (AVDL) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does AVADEL PHARMACEUTICALS have?
AVADEL PHARMACEUTICALS (AVDL) currently has 188 employees.
Can you provide the short interest for AVDL stock?
The outstanding short interest for AVADEL PHARMACEUTICALS (AVDL) is 4.36% of its float.
AVDL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AVDL. When comparing the yearly performance of all stocks, AVDL is one of the better performing stocks in the market, outperforming 95.5% of all stocks.
AVDL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AVDL. While AVDL seems to be doing ok healthwise, there are quite some concerns on its profitability.
AVDL Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| Debt/Equity | 0.35 |
AVDL Forecast & Estimates
16 analysts have analysed AVDL and the average price target is 21.48 USD. This implies a price decrease of -0.52% is expected in the next year compared to the current price of 21.59.
For the next year, analysts expect an EPS growth of 138.39% and a revenue growth 62.59% for AVDL